The current National Comprehensive Cancer Network (NCCN) guidelines recommend testing for RAS (KRAS and NRAS) and BRAF mutations and HER2 amplifications, individually or as part of an NGS panel, for all patients with metastatic CRC and universal MMR or microsatellite instability (MSI) testing in all newly diagnosed patients with CRC [8]. Here, ERBB2 is linked to colorectal carcinoma.